Status:
UNKNOWN
Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.
Lead Sponsor:
Hartford Hospital
Conditions:
Arrhythmia
Quality of Life
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study is being conducted to see if magnesium can reduce the number of shocks patients with ICDs experience and to see if magnesium supplementation improves patients quality of life.
Detailed Description
Not all ICD shocks are for ventricular arrhythmias. Some patients receive shocks when they have arrhythmias in the atria (top chambers of the heart). These are called inapproriate shocks, but the pain...
Eligibility Criteria
Inclusion
- newly implanted ICD or recent ICD shock (within 6 months) -
Exclusion
- inability to swallow, a non-cardiac disease with a survival prognosis of less than 12 months, hypermagnesemia, a creatinine clearance less than 30mL/min, lactic acidosis or systemic acidosis syndrome, or previous intolerance to magnesium L-lactate.
- \-
Key Trial Info
Start Date :
January 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2008
Estimated Enrollment :
240 Patients enrolled
Trial Details
Trial ID
NCT00282620
Start Date
January 1 2006
End Date
June 1 2008
Last Update
November 20 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hartford Hospital
Hartford, Connecticut, United States, 06102-5037